Redox Bioscience Inc.

Kyoto University

University of Iowa Research Foundation

Nippon Zoki Pharmaceutical Co., Ltd.

Kizakura Co., Ltd.

Junji Yodoi

Hajime Nakamura

Hiroshi Masutani

Tomohisa Horibe

Tsutomu Chiba

Tomijiro Hara

Richard G Lynch

Rafael M Nunez

Minoru Matsui

Akiyoshi Nishio

Kazuichi Okazaki

Hiroyuki Tamaki

Yuma Hoshino

Noriko Kato

Aoi Son

Norihiko Kondo

Shogo Tamasu

Kazuo Murata

Shingo Izawa

Yoshiharu Inoue

An object of the present invention is to provide a process for conveniently and efficiently producing high purity thioredoxin from yeast. In the production of thioredoxin using yeast, thioredoxin is produced through the following steps (i) to (iii):

Process for producing thioredoxin by stressing yeast cells

Disclosed is a screening method which can select a substance having an influence on the binding between thioredoxin and MIF. The screening method is characterized in that a test substance capable of enhancing the binding between a polypeptide belonging to the thioredoxin family and a macrophage migration inhibitory factor is selected through the steps of mixing at least one binding substance selected from the substances (1) to (4) shown below with the test substance, allowing the binding substance to bind to the macrophage migration inhibitory factor, and confirming the binding between the binding substance and the macrophage migration inhibitory factor: (1) a polypeptide belonging to the thioredoxin family; (2) a protein which comprises an amino acid sequence produced by deleting, substituting or adding one or several amino acid residues in an amino acid sequence for a polypeptide belonging to the thioredoxin family and has the same activity as that of a polypeptide belonging to the thioredoxin family; (3) a gene encoding the polypeptide (1); and (4) a gene encoding the protein (2).

Method of screening for a substance that strengthens a bond between thioredoxin and macrophage migration inhibition factor

A novel pharmaceutical application of an extract from a vaccine virus-inoculated and inflamed tissue and relates to a thioredoxin production promoting agent containing the extract as an active ingredient. The extract has an excellent thioredoxin production promoting action against an oxidative stress caused by a stimulus by such as a tobacco smoke extract or hydrogen peroxide and showed a significant lung cell protective effect. Therefore, the pharmaceutical of the invention containing the extract as an active ingredient is highly useful as a preventive or therapeutic agent for a chronic obstructive lung disease considered to be mainly caused by a continuous oxidative stress such as chronic smoking and the pharmaceutical with less side effects and high safety.

Agent for promoting the production of thioredoxin

The present invention provides a therapeutic agent for treating inflammatory bowel diseases comprising as an active ingredient at least one member selected from polypeptides belonging a family exhibiting thioredoxin activity.

Agent for treatment of inflammatory bowel disease

This invention discloses the isolation and purification of gene sequences which code upon expression a soluble form of the traditionally membrane bound immuno-regulatory protein, CD23. This protein regulates the amount of IgE present in the blood and upon cloning and amplification, procedures may be used in the treatment of IgE mediated diseases.

DNA sequences for soluble form of CD23

Growing community of inventors

Kyoto, Japan

Junji Yodoi